Progressive and unconventional pharmacotherapeutic approaches to alzheimer's disease therapy

Current Alzheimer Research

Volumn 9, Issue 1, 2012, Pages 1-4

  Maudsley, Stuart ^a   Chadwick, Wayne ^b  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b Takeda Pharmaceuticals   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CROCUS SATIVUS EXTRACT; DAIDZEIN; DONEPEZIL; ETANERCEPT; GALANTAMINE; GENISTEIN; GINKGO BILOBA EXTRACT; IMMUNOGLOBULIN G1; MEMANTINE; RIVASTIGMINE; SALVIA MILTIORRHIZA EXTRACT; TUMOR NECROSIS FACTOR RECEPTOR 2;

ALZHEIMER DISEASE; CLINICAL EFFECTIVENESS; DEMENTIA; DISEASE COURSE; DRUG EFFICACY; DRUG POTENCY; EDITORIAL; ENDOPLASMIC RETICULUM; GLUCOSE METABOLISM; HEALTH CARE COST; HEALTH CARE DELIVERY; HUMAN; INSULIN RESISTANCE; LONG TERM CARE; MILD COGNITIVE IMPAIRMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; SOCIOECONOMICS;

ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; COGNITION DISORDERS; HUMANS;

EID: 84856453919     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/156720512799015082     Document Type: Editorial

References (43)

1. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer's disease. Alzheimer's and Dementia 3(3): 186-191 (2007).
2. Wimo A, Jönsson L, Gustavsson A, McDaid D, Ersek K et al. The economic impact of dementia in Europe in 2008-cost estimates from the Eurocode project. Int J Geriatr Psychiatry 2010 Oct 28. [Epub ahead of print].
3. National Institutes of Health. Independent panel finds insufficient evidence to support preventive measures for Alzheimer's disease. Press release, April 28 (2010).
4. Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev 1: CD001190 (2006).
5. Raschetti R, Albanese E, Vanacore N, Maggini M. Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials. PLoS Med 4(11): e338 (2007).
6. US National Institutes of Health. http: //en.wikipedia.org/wiki/Alzheimer%27s_disease - cite_ref-234Clinical Trials. Found 858 studies with search of: Alzheimer. (2010)
7. Dodel R, Neff F, Noelker C, Pul R, Du Y, Bacher M, et al. Intravenous immunoglobulins as a treatment for Alzheimer's disease: rationale and current evidence. Drugs 70(5): 513-528 (2010).
8. Faux NG, Ritchie CW, Gunn A, Rembach A, Tsatsanis A et al. PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses. J Alzheimers Dis 20(2): 509-516 (2010).
9. Wang Y, Liu J, Zhang Z, Bi P, Qi Z, Zhang C. Anti-neuroinflammation effect of ginsenoside Rbl in a rat model of Alzheimer disease. Neurosci Lett 487(1): 70-72 (2011).
10. Chadwick W, Magnus T, Martin B, Keselman A, Mattson MP, Maudsley S. Targeting TNF-alpha receptors for neurotherapeutics. Trends Neurosci 31(10): 504-511 (2008).
11. Martin B, Golden E, Carlson OD, Pistell P, Zhou J, et al. Exendin- 4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease. Diabetes 58(2): 318-328 (2009).
12. Frolich L, Blum-Degen D, Bernstein HG, Engelsberger S, Humrich J, Laufer S et al. Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. J Neural Transm 105(4-5): 423-438 (1998).
13. Morris JK, Bomhoff GL, Stanford JA, Geiger PC. Neurodegeneration in an animal model of Parkinson's disease is exacerbated by a high-fat diet. Am J Physiol Regul Integr Comp Physiol 299(4): R1082-1090 (2010).
14. Martin B, Golden E, Keselman A, Stone M, Mattson MP, Egan JM, et al. Therapeutic perspective s for the treatment of Huntington's disease: treating the whole body. Histol Histopathol 23(2): 237-250 (2008).
15. Ferreira IL, Resende R, Ferreiro E, Rego AC, Pereira CF. Multiple defects in energy metabolism in Alzheimer's disease. Curr Drug Targets 11(10): 1193-1206 (2010).
16. Cho DH, Nakamura T, Lipton SA. Mitochondrial dynamics in cell death and neurodegeneration. Cell Mol Life Sci 67(20): 3435-3447 (2010).
17. Martin B, Brenneman R, Becker KG, Gucek M, Cole RN, Maudsley S. iTRAQ analysis of complex proteome alterations in 3xTgAD Alzheimer's mice: understanding the interface between physiology and disease. PLoS One 3(7): e2750 (2008).
18. Shin YK, Martin B, Golden E, Dotson CD, Maudsley S, et al. Modulation of taste sensitivity by GLP-1 signaling. J Neurochem 106(1): 455-463 (2008).
19. Martin B, Golden E, Carlson OD, Pistell P, Zhou J, et al. Exendin- 4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease. Diabetes 58(2): 318-328 (2009).
20. Shin YK, Martin B, Kim W, White CM, Ji S, Sun Y, et al. Ghrelin is produced in taste cells and ghrelin receptor null mice show reduced taste responsivity to salty (NaCl) and sour (citric acid) tastants. PLoS One 5(9): e12729 (2010).
21. Golden E, Emiliano A, Maudsley S, Windham BG, Carlson OD, et al. Circulating brain-derived neurotrophic factor and indices of metabolic and cardiovascular health: data from the Baltimore Longitudinal Study of Aging. PLoS One 5(4): e10099 (2010).
22. Martin B, Shin YK, White CM, Ji S, Kim W, Carlson OD, et al. Vasoactive intestinal peptide-null mice demonstrate enhanced sweet taste preference, dysglycemia, and reduced taste bud leptin receptor expression. Diabetes 59(5): 1143-1152 (2010).
23. Paz-Filho G, Wong ML, Licinio J. Leptin levels and Alzheimer disease. JAMA 303(15): 1478 (2010).
24. Une K, Takei YA, Tomita N, Asamura T, Ohrui T, et al. Adiponectin in plasma and cerebrospinal fluid in MCI and Alzheimer's disease. Eur J Neurol 2010 [Epub ahead of print]
25. Nicholson RM, Kusne Y, Nowak LA, LaFerla FM, Reiman EM, et al. Regional cerebral glucose uptake in the 3xTG model of Alzheimer's disease highlights common regional vulnerability across AD mouse models. Brain Res 1347: 179-185 (2010).
26. Schöll M, Almkvist O, Bogdanovic N, Wall A, Långström B, et al. Time course of glucose metabolism in relation to cognitive performance and postmortem neuropathology in Met146Val PSEN1 mutation carriers. J Alzheimers Dis 2011 [Epub ahead of print]
27. Stranahan AM, Zhou Y, Martin B, Maudsley S. Pharmacomimetics of exercise: novel approaches for hippocampally-targeted neuroprotective agents. Curr Med Chem 16(35): 4668-4678 (2009).
28. Thomsen T, Kewitz H. Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo. Life Sci 46(21): 1553-1558 (1990).
29. Wettstein A. Cholinesterase inhibitors and Gingko extracts-are they comparable in the treatment of dementia? Comparison of published placebo-controlled efficacy studies of at least six months' duration. Phytomedicine 6(6): 393-401 (2000).
30. Wang L, Martin B, Brenneman R, Luttrell LM, Maudsley S. Allosteric modulators of G protein-coupled receptors: future therapeutics for complex physiological disorders. J Pharmacol Exp Ther 331(2): 340-348 (2009).
31. Maudsley S, Martin B, Luttrell LM. G protein-coupled receptor signaling complexity in neuronal tissue: implications for novel therapeutics. Curr Alzheimer Res 4(1): 3-19 (2007).
32. Wang L, Chadwick W, Park SS, Zhou Y, Silver N, Martin B, Maudsley S. Gonadotropin-releasing hormone receptor system: modulatory role in aging and neurodegeneration. CNS Neurol Disord Drug Targets 9(5): 651-660 (2010).
33. Hogervorst E, Bandelow S. Sex steroids to maintain cognitive function in women after the menopause: a meta-analyses of treatment trials. Maturitas 66(1): 56-71 (2010).
34. Bates KA, Harvey AR, Carruthers M, Martins RN. Androgens, andropause and neurodegeneration: exploring the link between steroidogenesis, androgens and Alzheimer's disease. Cell Mol Life Sci 62(3): 281-292 (2005).
35. Choi YH, Hong SS, Shin YS, Hwang BY, Park SY, Lee D. Phenolic compounds from Pueraria lobata protect PC12 cells against Aβ- induced toxicity. Arch Pharm Res 33(10): 1651-1654 (2010)
36. Park YJ, Jang Y, Kwon YH. Protective effect of isoflavones against homocysteine-mediated neuronal degeneration in SHSY5Y cells. Amino Acids 39(3): 785-794 (2010).
37. Lee YJ, Han SB, Nam SY, Oh KW, Hong JT. Inflammation and Alzheimer's disease. Arch Pharm Res 33(10): 1539-1556 (2010).
38. Vegeto E, Benedusi V, Maggi A. Estrogen anti-inflammatory activity in brain: a therapeutic opportunity for menopause and neurodegenerative diseases. Front Neuroendocrinol 29(4): 507-519 (2008).
39. Kotakadi VS, Jin Y, Hofseth AB, Ying L, Cui X, et al. Ginkgo biloba extract EGb 761 has anti-inflammatory properties and ameliorates colitis in mice by driving effector T cell apoptosis. Carcinogenesis 29(9): 1799-1806 (2008).
40. Wallis WJ, Furst DE, Strand V, Keystone E. Biologic agents and immunotherapy in rheumatoid arthritis. Progress and perspective. Rheum Dis Clin North Am 24(3): 537-565 (1998).
41. Chadwick W, Magnus T, Martin B, Keselman A, Mattson MP, Maudsley S. Targeting TNF-alpha receptors for neurotherapeutics. Trends Neurosci 31(10): 504-511 (2008).
42. Tobinick E, Gross H, Weinberger A, Cohen H. TNF-alpha modulation for treatment of Alzheimer's disease: a 6-month pilot study. MedGenMed 8(2): 25 (2006).
43. Ukai H, Ueda HR. Systems biology of mammalian circadian clocks. Annu Rev Physiol 72: 579-603 (2010).